Clinical Trials | December 04, 2025
Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
The company is excluding data from the affected sites to maintain the study's integrity
The company is excluding data from the affected sites to maintain the study's integrity
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
Subscribe To Our Newsletter & Stay Updated
